

U.S. Influenza Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

<https://marketpublishers.com/r/U678874C306EN.html>

Date: November 2017

Pages: 214

Price: US\$ 2,400.00 (Single User License)

ID: U678874C306EN

Abstracts

U.S. Influenza Market

Influenza is an upper respiratory tract disease and is caused by the influenza virus. Influenza virus is mainly three types namely Influenza A, Influenza B, and Influenza C. Influenza is a communicable disease, spread through a flu cough, droplets from the infected people, sneeze or talks. The common symptoms occur in influenza patients are chills, cough, running nose, sore throat, body aches, headache, fatigue, some cases people may have vomiting and diarrhea. The complication of the disease may include ear infections, bacterial pneumonia, dehydration, sinus infections, and sometimes it leads to congestive heart failure, and asthma. Influenza commonly occurs in geriatric population and children with less than 5 years of age. The infection may be confirmed by testing the sputum, nose, or throat for the virus. A number of rapid tests are available however polymerase chain reaction that detects the virus's RNA is more accurate.

The U.S. Influenza market is growing at a significant CAGR due to rise in newborn babies, an increase in geriatric population. Increase in vaccination awareness, favorable reimbursement scenario, and rising investment by companies in research and development activities are the major factors fuelling the growth of U.S. influenza market over the forecast period. The major market players have great pipeline products, initiatives by government bodies such as WHO and CDC to control and prevent influenza, technological advancements in diagnostic tests also fuel the growth of U.S. influenza market over the forecast period. However, limited production capacity, a high level of required investment, and stringent regulatory policies for new product approvals might hamper the growth of U.S. Influenza market. Due to limitations in current technologies, the lengthy production times (approximately seven months), increase in

prices of influenza diagnostic kits and reagents also hinder the U.S. Influenza market.

The U.S. Influenza market is segmented on the basis of product type, distribution channel, and end user

Based on drug class, U.S. influenza market is segmented into the following:

Anti-viral drugs

Zanamivir

Oseltamivir

Amantadine

Rimantadine

Others

Interferons

Vaccines

Trivalent

Quadrivalent

Based on the route of administration, U.S. influenza market is segmented into the following:

Oral

Parenteral

Others

Based on distribution channel U.S. influenza market is segmented into the following:

Hospital pharmacies

Retail pharmacies

Others

Influenza vaccines are key revenue contributor for the growth of U.S. influenza market. The U.S. influenza market is in growing phase, several international players are actively involved in the development of vaccines and drugs to treat influenza. The launch of new products, technological innovations, and approvals from U.S. Food and Drug Administration (FDA) for various drugs might fuel the growth of U.S. influenza market. For instance, Squires used both egg and cell-based technologies to offer the broadcast portfolio of influenza vaccines in the U.S. for both trivalent and quadrivalent formulations. Similarly, transformative changes in other vaccine markets, due to the entrance of expensive and innovative vaccines such as Gardasil (Merck) and Bexsero (GSK) are projected to contribute growth of the U.S. influenza market.

U.S. holds a dominant share in the global influenza market. The largest share is attributed to the higher rate of in-vitro diagnostics availability and technological advancements in medical devices which are primarily driving the U.S. Influenza market growth. As per CDC, persons above 6 months of age could be vaccinated to prevent the influenza infection. Increase in prevalence and incidence cases of influenza (According to CDC, about 5 to 20 percent of the U.S. people are infected with influenza in every year. CDC also states that about 200,000 people hospitalized and more than 36,000 people are dying from influenza in U.S) might increase the growth of U.S. influenza market. Similarly, the upsurge in funding by the government is also driving the market growth in the United States. The U.S. government awarded 5-year contracts for more than US\$ 1 Bn to five drug manufacturers developing technology for speedier mass production of influenza vaccines

Some of the players in U.S. influenza market are AstraZeneca (U.K.), F. Hoffmann-La Roche (Switzerland), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Sanofi (France), Seqirus (U.K.), Protein Sciences Corporation (U.S.), Emergent Biosolutions (U.S.), BioCryst Pharmaceuticals Inc (U.S.), Alvogen (South Korea), Medimmune Inc. (U.S.), DynPort Vaccine Company, LLC. (U.S.), and Abbott Laboratories (U.S.) to name a few.

In May 2016, Seqirus received approval from U.S. Food and Drug Administration for Flucelvax Quadrivalent, that was the first U.S. licensed cell-based quadrivalent influenza vaccine indicated for people aged four years and older

In November 2016, GSK received approval from U.S. Food and Drug Administration for flulaval Quadrivalent to include use in children aged six months or older

Report Outline:

The report provides granular level information about the market size, regional market share, and forecast from 2017-2023

The report covers in-detail insights about the competitor's overview, key findings, and their key strategies

The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry

The report tracks recent innovations, key developments and startup's details that are working in the industry

The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario

Contents

1. EXECUTIVE SUMMARY

2. U.S. INFLUENZA MARKET INTRODUCTION

2.1. U.S. Influenza Market – Taxonomy

2.2. U.S. Influenza Market –Definitions

2.2.1. Drug Class Type

2.2.2. Route of Administration

2.2.3. Distribution Channel

3. U.S. INFLUENZA MARKET DYNAMICS

3.1. Drivers

3.2. Restraints

3.3. Opportunities/Unmet Needs of the Market

3.4. Trends

3.5. U.S. Influenza Market Dynamics – Factors Impact Analysis

3.6. U.S. Influenza Market – Regulations

3.6.1. U.S

3.6.2. Europe

3.6.3. Japan

3.6.4. China

3.7. U.S. Influenza Market – Product Innovations

4. U.S. INFLUENZA MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023

4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

4.3. Market Opportunity Analysis

5. U.S. INFLUENZA MARKET, BY DRUG CLASS, 2012 - 2016 AND FORECAST, 2017 - 2023

5.1. Anti Viral Drugs

5.1.1. Zanamivir

5.1.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD

Mn)

5.1.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.1.1.3. Market Opportunity Analysis

5.1.2. Oseltamivir

5.1.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD

Mn)

5.1.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.1.2.3. Market Opportunity Analysis

5.1.3. Amantadine

5.1.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD

Mn)

5.1.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.1.3.3. Market Opportunity Analysis

5.1.4. Rimantadine

5.1.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD

Mn)

5.1.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.1.4.3. Market Opportunity Analysis

5.1.5. Others

5.1.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD

Mn)

5.1.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.1.5.3. Market Opportunity Analysis

5.2. Vaccines

5.2.1. Trivalent

5.2.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD

Mn)

5.2.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.2.1.3. Market Opportunity Analysis

5.2.2. Quadrivalent

5.2.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD

Mn)

5.2.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis

5.2.2.3. Market Opportunity Analysis

6. U.S. INFLUENZA MARKET FORECAST, BY ROUTE OF ADMINISTRATION, 2012 - 2016 AND FORECAST, 2017 - 2023

6.1. Oral

- 6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
- 6.1.3. Market Opportunity Analysis
- 6.2. Parenteral
 - 6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
 - 6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
 - 6.2.3. Market Opportunity Analysis
- 6.3. Others
 - 6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
 - 6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
 - 6.3.3. Market Opportunity Analysis

7. U.S. INFLUENZA MARKET FORECAST, BY DISTRIBUTION CHANNEL, 2012 - 2016 AND FORECAST, 2017 - 2023

- 7.1. Hospital pharmacies
 - 7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
 - 7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
 - 7.1.3. Market Opportunity Analysis
- 7.2. Retail pharmacies
 - 7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
 - 7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
 - 7.2.3. Market Opportunity Analysis
- 7.3. Others
 - 7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
 - 7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
 - 7.3.3. Market Opportunity Analysis

8. U.S. INFLUENZA MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

- 8.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
 - 8.1.1. Anti-viral drugs
 - 8.1.1.1. Zanamivir
 - 8.1.1.2. Oseltamivir
 - 8.1.1.3. Amantadine
 - 8.1.1.4. Rimantadine
 - 8.1.1.5. Others
 - 8.1.1.6. Interferons

8.1.2. Vaccines

8.1.2.1. Trivalent

8.1.2.2. Quadrivalent

8.2. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

8.2.1. Oral

8.2.2. Parenteral

8.2.3. Others

8.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

8.3.1. Hospital Pharmacies

8.3.2. Retail Pharmacies

8.3.3. Others

8.4. U.S. Influenza Market - Opportunity Analysis Index, By Drug Class, Route of Administration, Distribution Channel and Country, 2017 – 2023

8.5. U.S. Influenza Market Dynamics – Trends

9. COMPETITION LANDSCAPE

9.1. Strategic Dashboard of Top Market Players

9.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)

9.2.1. AstraZeneca (UK)

9.2.2. F. Hoffmann-La Roche (Switzerland)

9.2.3. GlaxoSmithKline plc (UK)

9.2.4. Novartis AG (Switzerland)

9.2.5. Sanofi (France)

9.2.6. Seqirus (UK)

9.2.7. Protein Sciences Corporation (U.S.)

9.2.8. Emergent Biosolutions (U.S.)

9.2.9. BioCryst Pharmaceuticals, Inc. (U.S.)

9.2.10. Alvogen (South Korea)

9.2.11. Medimmune Inc. (U.S.)

9.2.12. DynPort Vaccine Company, LLC. (U.S.)

9.2.13. Abbott Laboratories (U.S.)

10. RESEARCH METHODOLOGY

11. KEY ASSUMPTIONS AND ACRONYMS

I would like to order

Product name: U.S. Influenza Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

Product link: <https://marketpublishers.com/r/U678874C306EN.html>

Price: US\$ 2,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/U678874C306EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

